Literature DB >> 17347328

Presence and phenotype of dendritic cells in uveal melanoma.

Marta E Polak1, Nicola J Borthwick, Penny Johnson, John L Hungerford, Bernie Higgins, Silvana Di Palma, Martine J Jager, Ian A Cree.   

Abstract

BACKGROUND: Uveal melanoma arises in an immune-privileged site and can itself add to the immunosuppressive environment. Previous studies on cutaneous melanoma have shown the presence of tolerogenic dendritic cells (DCs), which could play an important role in the progression of the tumour. AIM: To examine the presence and functional status of DCs in a small series of uveal melanomas.
METHODS: 10 cases of uveal melanoma were examined for the expression of FXIIIa, CD68, human leucocyte antigen (HLA)-DR, CD40, CD83, transforming growth factor betaR1 and indolamine 2,3 dioxygenase by immunohistochemical analysis on sections embedded in paraffin wax.
RESULTS: CD68-positive macrophages were present in all of the tumours and were evenly distributed throughout. DCs expressing FXIIIa-positive were seen in 7 cases, and were often found concentrated in foci within the tumour mass. These cells were dendritic and expressed high levels of HLA-DR. The DCs did not express the maturation markers CD83 or CD40. In one case, concentration of DCs around the area of tumour necrosis was observed, and some of these cells expressed CD83.
CONCLUSION: Numerous tolerising antigen-presenting cells may play a role in melanoma-related immunosuppression in the eye, although activation of DCs may be associated with tumour necrosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17347328      PMCID: PMC1955657          DOI: 10.1136/bjo.2006.110908

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  37 in total

Review 1.  Anterior chamber associated immune deviation (ACAID): regulation, biological relevance, and implications for therapy.

Authors:  Joan Stein-Streilein; J Wayne Streilein
Journal:  Int Rev Immunol       Date:  2002 Mar-Jun       Impact factor: 5.311

2.  The corneal stroma is endowed with a significant number of resident dendritic cells.

Authors:  Pedram Hamrah; Ying Liu; Qiang Zhang; M Reza Dana
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-02       Impact factor: 4.799

3.  Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?

Authors:  Manfred B Lutz; Gerold Schuler
Journal:  Trends Immunol       Date:  2002-09       Impact factor: 16.687

4.  Dead or alive: immunogenicity of human melanoma cells when presented by dendritic cells.

Authors:  M Shaif-Muthana; C McIntyre; K Sisley; I Rennie; A Murray
Journal:  Cancer Res       Date:  2000-11-15       Impact factor: 12.701

5.  The morphology, immunophenotype and distribution of paracortical dendritic leucocytes in lymph nodes regional to cutaneous melanoma.

Authors:  A M Lana; D R Wen; A J Cochran
Journal:  Melanoma Res       Date:  2001-08       Impact factor: 3.599

6.  Transforming growth factor-beta produced by progressor tumors inhibits, while IL-10 produced by regressor tumors enhances, Langerhans cell migration from skin.

Authors:  G M Halliday; S Le
Journal:  Int Immunol       Date:  2001-09       Impact factor: 4.823

7.  Apoptotic cell death in conjunction with CD80 costimulation confers uveal melanoma cells with the ability to induce immune responses.

Authors:  Jennifer Carlring; Munitta Shaif-Muthana; Karen Sisley; Ian G Rennie; Anna K Murray
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

8.  Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma.

Authors:  T Mäkitie; P Summanen; A Tarkkanen; T Kivelä
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-06       Impact factor: 4.799

9.  TGF-beta in uveal melanoma.

Authors:  P Esser; S Grisanti; K Bartz-Schmidt
Journal:  Microsc Res Tech       Date:  2001-02-15       Impact factor: 2.769

10.  Microcirculation and tumor-infiltrating macrophages in choroidal and ciliary body melanoma and corresponding metastases.

Authors:  Päivi Toivonen; Teemu Mäkitie; Emma Kujala; Tero Kivelä
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-01       Impact factor: 4.799

View more
  3 in total

Review 1.  Uveal melanoma as a target for immune-therapy.

Authors:  Marc Oliva; Antonio J Rullan; Josep M Piulats
Journal:  Ann Transl Med       Date:  2016-05

2.  Exploring the role of BAFF as biomarker in the detection of uveal melanoma metastases.

Authors:  Zenan Lin; Daniela Süsskind
Journal:  J Cancer Res Clin Oncol       Date:  2021-03-04       Impact factor: 4.553

3.  Influence of Tumor Location on the Composition of Immune Infiltrate and Its Impact on Patient Survival. Lessons from DCBCL and Animal Models.

Authors:  Claire Galand; Sabrina Donnou; Thierry Jo Molina; Wolf Herman Fridman; Sylvain Fisson; Catherine Sautès-Fridman
Journal:  Front Immunol       Date:  2012-05-04       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.